From GlobeNewswire: 2025-01-06 07:30:00

VYNE Therapeutics Inc. is currently evaluating the once-daily VYN201 gel in a Phase 2b trial for nonsegmental vitiligo, with top-line data expected in mid-2025. The USAN has approved “repibresib” as the non-proprietary name for VYN201. The trial is a double-blind study evaluating the efficacy of repibresib gel in three dose cohorts compared to a vehicle for 24 weeks. Vitiligo is a common depigmenting skin condition, and repibresib is a pan-bromodomain BET inhibitor designed to address inflammatory diseases. VYNE is focused on developing therapies for chronic inflammatory conditions, leveraging its InhiBET™ platform.



Read more at GlobeNewswire: VYNE Therapeutics Completes Enrollment in Phase 2b Trial